Bhardwaj Lab
@BhardwajLab
Laboratory of Dr. Nina Bhardwaj🔬 Immunology and Immunotherapy @TischCancer @SinaiImmunol. Posts by lab members
From @BhardwajLab and colleagues: Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type I Dendritic Cells for Cancer Immunotherapy Applications pubmed.ncbi.nlm.nih.gov/40600891/ mountsinai.org/about/newsroom… @IcahnMountSinai #cancervaccine
Just published in Cancer Immunology Research! Our lab reports the first scalable, serum-free production of bona fide, functional human cDC1s—generating ~3 billion from 1M HSCs. Read more: mountsinai.org/about/newsroom…
Atezolizumab in combination with personalized neoantigen vaccine for urothelial cancer. urotoday.com/recent-abstrac… via @urotoday @BhardwajLab @MattGalsky @IcahnMountSinai #bladdercancer
Excited for #CICON25 this September in Utrecht, Netherlands🇳🇱! A leading international meeting focused on advancing cancer immunotherapy. U.S. researchers are strongly encouraged to participate! 🗓 Abstracts due June 1 🔗 cancerimmunotherapyconference.org
By Mansi Saxena, @DrTomMarron, Philip Friedlander, @iskander, @BhardwajLab and colleagues @TischCancer @UNC
From the May issue: PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematological Malignancies in the Adjuvant Setting brnw.ch/21wSQPX
Nina Bhardwaj, MD, PhD, is pleased to serve as Co-Chair of #CICON25. cancerimmunotherapyconference.org Registration is open now. @BhardwajLab
Join us at #CICON25, from September 10-12, as we explore exciting new research in cancer immunotherapy, and shape new strategies that translate scientific discoveries into life-changing outcomes! Review the program, and register today: bit.ly/4cjiDJ4 #CancerResearch
Results from a phase 1 study led by Drs. Nina Bhardwaj and @MattGalsky show that their custom-made vaccine, in combination with immune checkpoint inhibitor, is safe and able to spark strong immune responses in people with #BladderCancer. @BhardwajLab @TischCancer @NatureCancer
Matt Galsky, Nina Bhardwaj, and team show that custom-made vaccine, in combination with immune checkpoint inhibitor, sparks strong immune responses in people with #BladderCancer. mountsinai.org/about/newsroom… @MattGalsky @BhardwajLab @IcahnMountSinai
See our study in @NatureCancer evaluating personalized neoantigen vaccine + atezo in urothelial cancer First report in the adjuvant setting for UC, randomized phase 2s ongoing @MattGalsky @BhardwajLab @TischCancer @Uromigos @BladderCancerUS @urotoday nature.com/articles/s4301…
We tested the feasibility and immunogenicity of a personalized neoantigen vaccine + PD-L1 blockade in #bladdercancer including the adjuvant setting. nature.com/articles/s4301… @JonAnker1 @BhardwajLab @urotoday @Uromigos @TischCancer @FaltasLab @NatureCancer @BladderCancerUS
Belated post: last month we said goodbye to @JennaNewmanPhD, who was a postdoctoral fellow in the lab for 5 years. Congratulations on your exciting new journey as a Senior Scientist at @AstraZeneca! You’ve been a fantastic member of our lab in so many ways & we miss you already!
Grateful to the @GOG for the opportunity to present our research at fellows forum and honored to receive the best overall presentation award! @StephanieVBlank @BhardwajLab @matt_brown04 @IcahnMountSinai @TischCancer
Personalized cancer vaccine proves promising in a phase 1 trial medicalxpress.com/news/2025-03-p… via @medical_xpress @BhardwajLab @IcahnMountSinai
Congratulations to several members of our Vaccine and Cell Therapy Laboratory, past and present, on the publication of our PGV neoantigen vaccine trial data in Cancer Discovery! 🥳
PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting aacrjournals.org/cancerdiscover… @BhardwajLab Thomas Marron, MD, PhD @IcahnMountSinai
Congratulations to Dr. Nina Bhardwaj on being named a Fellow of the @AACR Academy Class of 2025. @BhardwajLab
Congratulations to Nina Bhardwaj @BhardwajLab @IcahnMountSinai, named a Fellow of the @AACR Academy Class of 2025. aacr.org/about-the-aacr…
Congratulations @NinaBhardwaj !
👏 Congratulations to CRI Scientific Advisory Council Associate Director Dr. Bhardwaj @BhardwajLab @IcahnMountSinai and CRI SAC member Dr. Vonderheide @PennMedicine, who have been named Fellows of the @AACR Academy Class of 2025! Learn more: bit.ly/3DuLRYy #AACRFellows
Updated lab photo! Today we celebrated postdoctoral fellow Kazuki Sone, whose last day in the lab is tomorrow, before he heads to Japan for a Chief Researcher position. Thank you Kazuki for being a fantastic scientist and labmate, and congratulations on your new role!
Francis Collins resigned from NIH yesterday. He rightly pointed out that it's Human Genome Project revolutionized every aspect of biomedical research. He points out that NIH has historically been sens as high priority and non partisan. 1/
Pitt to pause PhD admissions, following Vanderbilt and USC, because of uncertainty of NIH funding to academic universities. Who will teach and train US scientists for pharma and biotech? Should we import them from countries that do? wesa.fm/health-science…
SITC is deeply concerned by the announcement from NIH that will cut billions of dollars in indirect costs. We urge the NIH & the new administration to reverse this action to ensure life-saving cancer treatments continue to reach the clinic and patients. sitcancer.org/advocacy/indir…